Last reviewed · How we verify
Ticagrelor alone
At a glance
| Generic name | Ticagrelor alone |
|---|---|
| Also known as | Brilique |
| Sponsor | University Hospital, Bordeaux |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- Ticagrelor Monotherapy After Stenting (PHASE2)
- Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone (PHASE3)
- Bariatric Surgery for the Reduction of cArdioVascular Events Randomized Controlled Trial (NA)
- STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT (NA)
- Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk (NA)
- Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38) (NA)
- PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |